Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia

Elena Andreeva | Yulia Absatarova

Abstract
Objective: To evaluate the effectiveness of triptorelin for the treatment of adenomyosis, the benign invasion of endometrial tissue into the myometrium, as a fertility-preserving alternative to the gold standard hysterectomy.

Methods: In this multicenter, open-label, observational study in Russia, performed from November 3, 2011, to August 24, 2015, we assessed the efficacy and safety of triptorelin 3.75 mg administered intramuscularly every 28 days in Russian women who were gonadotropin-releasing hormone agonist treatment-naïve, aged 25–40 years, and had a diagnosis of endometriosis or adenomyosis with heavy menstrual bleeding. We performed a medical record review, interviews to assess symptom severity, and pelvic assessments including transvaginal ultrasound. Data were obtained at first injection of triptorelin (visit 1), on the day of last injection (visit 2), 6 months after last injection (visit 3), and 9 months after last injection (visit 4). Significance was assessed by Wilcoxon signed rank test.

Results: A total of 465 women were included. There was a significant improvement from baseline in severity of heavy menstrual bleeding in 390/463 (84.2%) of women 6 months after last injection ($P<0.0001$). Severity of dysmenorrhea, abnormal uterine bleeding, and pelvic pain was decreased at visit 3 compared with baseline ($P<0.0001$). Endometriosis symptoms stopped in 253/262 (96.6%) of women at visit 2 and in 243/263 (92.4%) of women at visit 3. Pregnancy was reported in 116/465 (24.9%) women within 9 months following the end of treatment.

Conclusion: Triptorelin has a favorable safety profile, is highly efficacious in treating clinical symptoms of adenomyosis, and improves reproductive function.

ClinicalTrials.gov registration number: A-38-52014-191, registered October 2011.

KEYWORDS
Adenomyosis; Dysfunctional uterine bleeding; Dysmenorrhea; Endometriosis; Fertility; Pain; Pregnancy; Triptorelin

1 | INTRODUCTION

Endometriosis is a common gynecologic disease occurring worldwide in approximately 10% of women of childbearing potential, 38%–50% of infertile women, and almost 87% of women with chronic pelvic pain. Adenomyosis is a form of endometriosis that is characterized by benign endometrial invasion into the myometrium, leading to diffuse enlargement of the uterus, which manifests with ectopic...
endometrial glands and stroma surrounded by hypertrophic and hyperplastic myometrium. The prevalence of adenomyosis at hysterectomy ranges from 5% to 70% of women. Symptoms of adenomyosis include menstrual disorders and persisting pain syndrome, which can reduce quality of life. Adenomyosis can also impair reproductive function, resulting in infertility, by affecting uterotubal transport and altering endometrial function and receptivity. In 50% of cases, adenomyosis can reduce the likelihood of pregnancy occurring naturally. Women with adenomyosis have poor reproductive outcomes compared with those without adenomyosis. Limited data are available concerning the efficacy of different treatment options in improving fertility. The most common comorbidity of adenomyosis is uterine fibroids (80%–85% of cases), which may result from similar pathogenic mechanisms.

Hysterectomy is used worldwide to treat adenomyosis in premenopausal and perimenopausal women with severe clinical symptoms, however, this major surgery can cause complications, reduce quality of life, and incur high economic costs. Adenomyosis is more prevalent among women of childbearing potential than previously thought, and alternative treatment options are required to preserve reproductive function.

Gonadotropin-releasing hormone (GnRH) agonists are used in nonsurgical therapy for all forms of endometriosis, as both main and adjuvant therapy. This treatment reduces both the intensity of endometriosis symptoms and uterine volume.

Triptorelin acetate 3.75 mg, a 28-day, prolonged-release GnRH agonist approved for endometriosis treatment, has been shown to decrease endometriosis symptom severity and improve reproductive function. However, no large-scale clinical trials of triptorelin have been performed in women with adenomyosis. We conducted a large, multicenter, observational study to evaluate the effectiveness of triptorelin to treat adenomyosis in routine clinical practice.

2 | MATERIALS AND METHODS

A national, multicenter, open-label, observational, non-interventional study (Clinical Trials.gov number A-38-52014-191) was performed between November 3, 2011, and August 24, 2015, at 33 study sites in the Russian Federation. The study included GnRH agonist treatment-naive women aged 25–40 years with adenomyosis and heavy menstrual bleeding (HMB). Diagnosis was based on uterine enlargement observed during bimanual pelvic and transvaginal ultrasound (TVUS) examinations, performed within 2 months before the first study-drug injection. Endometriosis disease severity (stage I, II, or III) was categorized using criteria routinely employed in Russia for evaluation of adenomyosis (Table S1). To avoid recruitment bias, investigators recruited all consecutive patients meeting the inclusion criteria to the study.

Study exclusion criteria included pregnancy, previous treatment with or hypersensitivity to GnRH analogs, and participation in another clinical study (at enrollment and within the last 30 days). The decision to prescribe triptorelin was at the investigator’s discretion and was made before and independently of the decision to enroll a patient.

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was approved by an Independent Interdisciplinary Committee on Ethical Review of Clinical Studies and all patients provided written, informed consent before the study began.

Triptorelin acetate 3.75 mg (Diphereline [Ferring Holding SA, Saint-Prex, Switzerland]) was administered intramuscularly every 28 days for up to 6 months, in line with prescribing information and clinical practice standards.

Data were collected by the investigators at each study site at four study visits. At visit 1, baseline data were collected on-site on the day of the first triptorelin injection. Follow-up data were obtained at: visit 2 (on-site), last triptorelin injection; visit 3 (on-site/telephone interview), 6 months after last injection; and visit 4 (telephone interview), 9 months after last injection. Accurate data reporting and protocol compliance were monitored by a data monitor. Data management and statistical analysis were conducted by a contracted clinical research organization (CRO) in accordance with sponsor and CRO standard operating procedures.

At visits 1 and 2, endometriosis symptom intensity (pelvic pain, dysmenorrhea, HMB, and abnormal uterine bleeding [AUB]) was assessed according to the PALM-COEIN (polyp; adenomyosis; leiomyoma; malignancy and hyperplasia; coagulopathy; ovulatory dysfunction; endometriosis; iatrogenic; and not yet classified) classification system, monitored during the previous month by the patient using a four-grade scale: none, mild, moderate, or severe. Bimanual pelvic and TVUS examinations were performed at visits 1 and 2. During visit 1, results were collected from TVUS performed within 2 months before first injection (TVUS was conducted during the first 5–10 days of the menstrual cycle). At visit 3, intensity of endometriosis symptoms was assessed and cases of clinical pregnancy or surgical treatment of endometriosis were recorded; at visit 4, only cases of pregnancy or surgical treatment of endometriosis were recorded.

The primary study objective was evaluation of triptorelin effectiveness, assessed by reduction in HMB intensity 6 months after last injection (visit 3). Patients with a decrease in HMB intensity by at least one grade were considered treatment responders. The secondary objectives were to determine: endometriosis symptoms intensity by disease stage (I, II, or III) at end of treatment (visit 2) and 6 months after last injection (visit 3); uterine volume by endometriosis disease stage at end of treatment; and reproductive function 6 and 9 months after last injection by endometriosis disease stage. The change in intensity of each endometriosis symptom was calculated separately; complete treatment response was defined as a decrease in intensity of all endometriosis symptoms by at least one grade. Additional, equivalent analyses were conducted for patients with adenomyosis and uterine myoma.

Anteroposterior uterine size and uterine volume were assessed by TVUS (visits 1 and 2). Uterine volume (cm$^3$) was calculated using the formula $0.5230 \times a \times b \times AP$, where $a$ and $b$ are uterine length and width, respectively, and $AP$ is anteroposterior uterine size. Reproductive function was assessed by the number of recorded clinical pregnancies.

Spontaneously occurring safety events were recorded according to the registered drug’s safety procedure; investigators registered and
reported to the manufacturer’s pharmacovigilance department any drug-related adverse events or serious adverse events via a spontaneous adverse event report form. Adverse events considered by the investigator to be unrelated to the study drug were not collected.

Collected data were analyzed using software SAS version 9.2 (SAS Institute, Cary, NC, USA). Data were expressed using descriptive statistics (mean, standard deviation [SD], median, minimal and maximal value, range, and number of valid cases for quantitative variables; and number, percentage, and distribution for qualitative variables). A P value less than or equal to 0.05 was considered statistically significant. Two-sided 95% confidence intervals (CI, Clopper-Pearson for qualitative variables) were also presented where relevant. The evolution of severity of symptoms compared with baseline conditions was assessed using a Wilcoxon signed rank test. The sample size calculation was based on the assumption that 10% of patients scheduled to receive GnRH treatment had stage I disease. Inclusion of 400 patients would allow an estimate of the proportion of overall responders with a precision of 4.9%, and of stage I patients with a precision of 15.5% (assuming a two-sided 95% CI). Assuming that 20% of the patients would be non-evaluable, up to 500 patients were calculated as needing to be enrolled to give sufficient power to the statistical analyses.

Data from the following study populations were assessed: screened set—patients who had completed screening and had given written informed consent; enrolled set—screened patients who had given written informed consent and were included in the study; effectiveness population—all enrolled patients with HMB symptom-severity data at baseline, who received at least one triptorelin 3.75 mg injection and had at least one post-baseline assessment of menorrhagia symptom severity; and per protocol population—all patients included in the effectiveness population for whom no major protocol deviations occurred.

3 | RESULTS

In total, 463 patients (99.6%) completed all study assessments (visits 1–4). Two patients discontinued the study, one after visit 2 and one after visit 3 (Fig. S1). Baseline demographic and disease characteristics are summarized in Table 1. Mean ± SD age at study enrollment was 32.5 ± 4.56 years (range, 22–43 years). The majority of patients were categorized with endometriosis stage II at baseline (246/465 patients [52.9%]) according to Demidov criteria.18 During the study, 186 women (40.0%) received four injections, 169 (36.3%) received six injections, and 90 (19.4%) received three injections. Data for one patient were missing at visit 3. The mean ± SD duration of exposure to triptorelin was 101.4 ± 34.74 days (Table S2). In total, 59 women (12.7%) had active myoma at baseline. During the study, 95 women (20.4%) received additional treatment for endometriosis (progestogens, 54/465 [11.6%]; combined oral contraceptives, 39/465 [8.4%]; and other medication, 9/465 [1.9%]).

At baseline, all patients reported HMB. Treatment with triptorelin eradicated HMB in 390/463 (84.2%) women up to 6 months after the last injection (visit 3; P<0.0001; Fig. 1); this effect was observed regardless of endometriosis severity. At visit 2, for the 10 women who reported HMB, intensity was mild (7/465 [1.5%]) or moderate (3/465 [0.6%]). The number of women symptomatic for HMB increased between visits 2 and 3 by 13.5% (visit 2: 10/465 [2.2%], visit 3: 73/463 [15.7%], Fig. 1). At visit 3, the intensity of HMB was mild (59/464 [12.7%]) or moderate (14/464 [3.0%]); no severe cases were reported. Nearly all women responded to treatment (visit 2: 462/465 [99.4%]; visit 3: 453/463 [97.8%]); this was observed for all endometriosis stages (Table 2). For the 59 women with adenomyosis and myoma at baseline, 48/59 (81.4%) patients reported an absence of HMB at visit 3; 9/59 (15.3%) patients had mild symptoms, 2/59 (3.4%) patients had moderate symptoms, and no patients had severe symptoms; 55/59 (93.2%) of these patients had responded to treatment at visit 3 (Table S3).

| TABLE 1 | Baseline patient and disease characteristics (enrolled set) |
|---------|-----------------------------------------------------------|
| Women who received triptorelin (N=465) | |
| Age, years | Mean ± SD (range) |
| 32.5 ± 4.56 (22–43) |
| Age at first diagnosis, years | Mean ± SD (range) |
| 31.2 ± 4.55 (20–43) |
| Stage of endometriosis, n (%) | |
| Stage I | 125 (26.9) |
| Stage II | 246 (52.9) |
| Stage III | 94 (20.2) |
| Age of menarche, years | Mean ± SD (range) |
| 13.0 ± 1.24 (10–17) |
| Infection, n (%) | |
| Infertility | 224 (48.2) |
| Primary | 116 (51.8) |
| Secondary | 108 (48.2) |
| Proportion of women who have had at least one pregnancy, n (%) | |
| 284 (61.1) |
| Number of pregnancies | Mean ± SD (range) |
| 2.5 ± 2.09 (1–19) |
| Concurrent gynecologic disease, n (%) | |
| 379 (81.5) |
| Surgical interventions, n (%) | |
| Laparoscopy | 156 (33.5) |
| Ovarian cystectomy | 78 (16.8) |
| Ablation of endometriotic nodes | 69 (14.8) |
| Hysteroscopy | 50 (10.8) |
| Dilation and curettage of uterus | 48 (10.3) |
| Myomectomy | 36 (7.7) |
| Previous therapies at baseline, n (%) | |
| 109 (23.4) |
| Oral contraceptives | 73 (15.7) |
| Progestogens | 45 (9.7) |
| Danazol | 2 (0.4) |
| Mifepristone | 2 (0.4) |

*Effectiveness set.*
At baseline, the following proportion of women reported symptoms of: dysmenorrhea, 423/465 (91.0%); AUB, 302/465 (64.9%); and pelvic pain, 398/465 (85.6%; Figs 2–4). At baseline, pelvic pain was typically moderate (222/465 [47.7%]) or severe (109/465 [23.4%]) in intensity (Table S4).

At visit 3, a significant increase from baseline was observed in the proportion of women without dysmenorrhea symptoms (386/463 [83.4%], P<0.0001; Fig. 2), without AUB (435/463 [94.0%], P<0.0001; Fig. 3), and without pelvic pain (367/463 [79.3%], P<0.0001; Fig. 4). For each of these secondary outcomes, a significant benefit of treatment for each stage of endometriosis was observed at visit 3 (all P<0.0001; Figs 2–4). Similar to the primary outcome, the proportion of patients with symptoms of dysmenorrhea and AUB increased slightly from visit 2 to visit 3 (19/465 [4.1%] vs 77/463 [16.6%], Fig 2; 8/465 [1.7%] vs 28/463 [6.0%], Fig 3). The proportions of women without any symptoms of pelvic pain were similar at visits 2 and 3 for the overall population (97/465 [20.9%] vs 96/463 [20.7%], Fig 4), and at each stage of endometriosis (stage I, 19/125 [15.2%] vs 19/124 [15.3%]; stage II, 57/246 [23.2%] vs 54/245 [22.0%]; stage III, 21/94 [22.3%] vs 23/94 [24.5%], Fig 4).

At visit 3, a high proportion of women had responded to treatment for dysmenorrhea, 412/422 (97.6%), AUB, 296/301 (98.3%), and pelvic pain, 387/398 (97.2%) (Table 2); findings were numerically similar at study visit 2. Women with adenomyosis and myoma also responded to treatment for each of these secondary outcomes (97.8%–98.2%; Table 2).

A complete treatment response was observed at visit 3 in 92.4% of the overall study population with available data (243/263 patients; Table 2). Similar proportions of patients had a complete treatment response for each stage of endometriosis (stage I, 43/49 [87.8%]; stage II, 144/154 [93.5%]; stage III, 56/60 [93.3%]) and for women with adenomyosis and myoma (40/44 [90.9%]). This treatment pattern was also observed at study visit 2 (Table 2).

### TABLE 2 Proportion of women who responded to treatment by study outcome and by complete treatment response (effectiveness set)

| Visit | Overall study population | Stage I endometriosis | Stage II endometriosis | Stage III endometriosis | Patients with adenomyosis and myoma |
|-------|--------------------------|-----------------------|------------------------|-------------------------|-------------------------------------|
| Visit 2 | 462/465 (99.4) | 124/125 (99.2) | 244/246 (99.2) | 94/94 (100) | 59/59 (100) |
| Visit 3 | 453/463 (97.8) | 124/125 (99.2) | 239/245 (97.6) | 91/94 (96.8) | 55/59 (93.2) |

Data are presented as n (%).

*aTreatment response is defined by a decrease of at least one grade in symptom intensity for those with at least mild intensity symptoms at baseline.

*bPatients responded to pain relief.

*cComplete treatment response is defined by a decrease of at least one grade in symptom intensity for all symptoms for those with at least mild intensity of symptoms at baseline.

By end of treatment (visit 2), the proportion of women with stage II or III endometriosis had significantly decreased from baseline (P<0.0001): At baseline, 246/465 (52.9%) had stage II and 94/465 (20.2%) had stage III, whereas at visit 2, 73/376 (19.4%) had stage II and 2/376 (0.5%) had stage III. A total of 89 patients were classified as having “missing data” because they had improvements that corresponded to “no signs of adenomyosis,” which was not an option on the database (Fig. S2).

The changes from baseline in ultrasonic parameters at visit 2 were summarized in Table 3. At visit 2, reductions from baseline in uterine length, width, wall thickness, anteroposterior dimension, and volume were observed (Table 3). Bimanual pelvic examination findings are reported in Table S5, and indicate a beneficial effect of triptorelin treatment on uterine size, shape, mobility, and tenderness.
adverse events were reported during the study and for each endometriosis stage; significance was calculated using a Wilcoxon signed rank test. One patient discontinued after visit 2.

Pregnancy was reported following end of treatment by 116 of 465 women (24.9%; Table 4); of the 116 pregnancies, 113 (97.4%) were planned, and two abortions took place (0.4%). A total of 32 pregnancies (17.9%) occurred in the 179 women aged 35 years or older (Table 4). In total, 4 of 465 (0.9%) women received a surgical intervention following end of triptorelin treatment; hysterectomy was performed on 1 of 465 (0.2%) women with stage III disease.

In total, 149 adverse events were reported during the study, the most frequent being hot flush (n=66), followed by irritability (n=10), sleep disorders (n=7), and tearfulness (n=4; Table S6). No serious adverse events were reported during the study.

4 | DISCUSSION

The results suggest that intramuscular triptorelin acetate 3.75 mg offers an effective treatment for women with adenomyosis and has an acceptable safety profile. The primary study outcome was met, and significant and consistent effects on dysmenorrhea, AUB, and pelvic pain were also reported, regardless of disease stage. Overall, symptoms were improved (complete treatment response) in 96.6% of women at visit 2 and 92.4% of women at visit 3. Of note, triptorelin was effective in patients with concurrent uterine pathology; in patients with myoma, a complete treatment response was observed at visit 2 in 97.7% of women and maintained 6 months after last injection in 90.9% of women (visit 3). Nearly all patients experienced an improvement of endometriosis; by end of treatment (visit 2), only two patients were classified with stage III endometriosis.18 Our results confirm other findings showing that triptorelin decreases HMB manifestations and pain in patients with endometriosis, adenomyosis, and uterine myoma.14–16 This is noteworthy given the high proportion of patients with stage II or III endometriosis, concurrent gynecologic diseases, and different forms of endometriosis in our study population.

During triptorelin treatment, a decrease from baseline in uterine size and volume was observed, which confirms previous findings.14,15 Similarly, bimanual pelvic examination revealed reduced uterine size and diminished tenderness at palpation in most patients after treatment. The uterus became softer and returned to a normal (nonspherical) shape, with improved mobility, suggesting reduced adhesive processes in the pelvic cavity.

Adenomyosis treatment options are hormonal therapy, conservative surgery, and hysterectomy. The first drugs licensed for this purpose were GnRH analogs. The pronounced effect of triptorelin (and other GnRH analogs) on the course of endometriosis may be attributed to its capacity to suppress estrogen synthesis, as well as to its ability to inhibit endometrioid foci growth by decreasing the synthesis of anti-inflammatory cytokines and stimulating apoptosis of ectopic endometrioid cells.10 Additionally, GnRH analogs can suppress angiogenesis, decreasing vascular growth factor synthesis.4,10,23 Given their multiple effects on the endometrium and myometrium, GnRH analogs...
could be considered as pathogenic adenomyosis treatments. This drug class has specific advantages in women with a combination of adenomyosis and uterine myoma. The mechanism of myoma growth inhibition by GnRH analogs is mediated by hypoestrogenic induction, suppression of proliferation (decrease in Ki-67 expression), increased apoptosis of myoma cells, and significant reduction in expression of all main growth factors and their receptors. The potential of GnRH analogs to induce apoptosis in the endometrium and simultaneously reduce uterine volume, menstrual blood loss, and size of myomatous nodes has been shown in multiple studies.

The positive effect of triptorelin on reproductive function is also of interest. Difficulty in becoming pregnant was diagnosed at baseline in almost half of the enrolled patients, in keeping with previous studies; just under two-thirds had at least one previous pregnancy before inclusion in the study. After triptorelin treatment, pregnancy was reported in approximately one-quarter of patients. Markedly, 18% were in women aged 35 years or older, and 20% of all women received contraception as follow-up treatment. Our data confirm previous results indicating that triptorelin and other GnRH agonists can improve fertility in 20%–25% of women with adenomyosis, independent of stage, within 1 year after treatment completion.

Notably, triptorelin treatment helped to avoid surgical intervention; only one hysterectomy was performed (0.2%), in a woman with endometriosis stage III. Thus, triptorelin may be considered an effective treatment option for women who wish to maintain their reproductive potential. Furthermore, there is growing evidence of long-term, negative health consequences of hysterectomy compared with natural menopause.

A favorable safety profile of triptorelin was observed during the study treatment period. Only well-known adverse events were observed, and no serious adverse events were reported. Previously, in a Russian multicenter observational study of triptorelin in patients with endometriosis (N=1000), only 11.3% of patients reported hot flushes during the 4–6-month study, none of which required additional treatment.

During the current study, 20.4% of patients used additional drugs to treat adenomyosis. Because GnRH agonists cannot be used continuously owing to development of estrogen-deficiency symptoms, this raises an important question concerning the need for additional treatments. Hirata et al. showed that dienogest administration for symptomatic treatment of adenomyosis significantly decreased pelvic pain; however, increased menstrual bleeding was observed in some patients. Additionally, studies have evaluated the potentiating of treatment efficacy and duration after consecutive administration of a GnRH agonist and dienogest (2 mg/d) in women with recurrent endometriosis, and with combined uterine pathology. Consecutive treatment in cases of severe endometriosis and/or combined uterine pathology may be a promising treatment approach. There are several study limitations to note. Due to the multicenter study design, there may be some biases based on symptom reporting, and potential variations in ultrasound findings because of minor differences in sensitivity of the ultrasound echo between study sites.

### TABLE 3  Change from baseline in ultrasonic parameters at study visit 2 with triptorelin treatment (effectiveness set)

| Parameter                          | Baseline (visit 1) (N=465) | Visit 2 (N=465) | Change in parameter from baseline |
|-----------------------------------|-----------------------------|----------------|----------------------------------|
| Uterine length, cm                | 6.1 ± 1.3                   | 5.1 ± 0.8      | −1.0 ± 1.1 (−1.1, −0.9)          |
| Uterine width, cm                 | 5.8 ± 1.4                   | 4.8 ± 0.8      | −0.9 ± 1.1 (−1.0, −0.8)          |
| Mean uterine wall thickness, cm   | 1.0 ± 0.9                   | 0.5 ± 0.6      | −0.5 ± 0.5 (−0.6, −0.5)          |
| Anteroposterior size, cm          | 5.5 ± 1.4                   | 4.5 ± 1.0      | −1.0 ± 1.0 (−1.1, 0.9)           |
| Uterine volume, cm³               | 119.3 ± 169.3               | 62.5 ± 32.7    | −56.7 ± 159.3 (−71.2, −42.1)    |

Abbreviation: SD, standard deviation. All values are presented as mean ± SD (95% confidence interval).

### TABLE 4  Summary of pregnancy cases following end of triptorelin treatment (enrolled set)

| Overall study, n | Any pregnancy since end of treatment | Any pregnancy at 6 months post-treatment (visit 3) | Any pregnancy at 9 months post-treatment (visit 4) since visit 3 |
|------------------|--------------------------------------|-----------------------------------------------|---------------------------------------------------------------|
| Overall study, n | 465                                  | 464                                           | 463                                                          |
| All pregnancies  | 116 (24.9)                           | 57 (12.3)                                     | 59 (12.7)                                                    |
| Planned pregnancy | 113 (97.4)                           | 55 (96.5)                                     | 58 (98.3)                                                    |
| Unplanned pregnancy | 3 (2.6)                              | 2 (3.5)                                       | 1 (1.7)                                                      |
| Women ≥35 years old, n | 179                                  | 179                                           | 179                                                          |
| All pregnancies  | 32 (17.9)                            | 16 (8.9)                                      | 16 (8.9)                                                     |
| Planned pregnancy | 31 (96.9)                            | 16 (100)                                      | 15 (93.8)                                                    |
| Unplanned pregnancy | 1 (3.1)                             | 0 (0)                                         | 1 (6.3)                                                      |

All data are presented as n (%) unless otherwise stated.
In conclusion, treatment with intramuscular triptorelin acetate 3.75 mg decreased the clinical symptoms of adenomyosis in almost all patients. Considering the favorable safety profile as well as the capacity to improve reproductive function, triptorelin may be considered as a treatment option for adenomyosis, particularly in young women who wish to preserve reproductive potential.

AUTHOR CONTRIBUTIONS
EA and YA contributed to the study design and implementation. Both authors analyzed and interpreted the study data. Both authors contributed in writing the manuscript and both authors read and approved the final manuscript.

ACKNOWLEDGMENTS
The study was funded and sponsored by Ipsen. The authors thank all patients involved in the study, as well as their caregivers, care teams, investigators, and research staff in participating institutions. Tatiana Gorskaya, of Ipsen, was involved in the study design, interpretation of findings and manuscript development. The authors thank Sarah Griffiths, PhD, of Oxford PharmaGenesis Ltd, Oxford, UK, who provided editorial support, which was funded by Ipsen, in accordance with Good Publication Practice guidelines.

CONFLICTS OF INTEREST
The authors have no conflicts of interest.

REFERENCES
1. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116:223–236.
2. Andreeva EN, Yarotskaya EL, Adamyan LV. Russian clinical profile of patients with a diagnosis of ‘genital endometriosis’ treated with agonists of gonadotropin-releasing hormone. The results of the Russian open multicenter observational study. [Клинический профи́лъ российских пациенток с диагнозом ‘генитальный эндометрио́з’, получавших лечение агонистами гонадотропин рилизинг-гормона. Результаты российского открытого многоцентрового наблюдательного исследования] Article in Russian. Problems in Reproduction. 2011;17:50–62.
3. Andreeva EN, Yarotskaya EL, Poznyakova EV. Safety and efficacy of triptorelin 3.75 mg to treat Russian patients diagnosed with ‘genital endometriosis’. Results of a multicenter Russian open post-marketing observational study. [Безопасность и эффективность применения трипторелина 3,75 мг для лечения российских пациентов с диагнозом ‘генитальный эндометрио́з’. Результаты российского открытого постмаркетингового многоцентрового наблюдательного исследования] Article in Russian. Kremlin Med. 2011; 4:134–143.
4. Sidorov IS, Hunayan AL. A differentiated approach to the treatment of adenomyosis. Obstet Gynecol Reprod. 2011;5:16–20.
5. Taran FA, Stewart EA, Brucker S. Adenomyosis: epidemiology, risk factors, clinical phenotype and surgical and interventional alternatives to hysterectomy. Geburtshilfe Frauenheilkd. 2013;73:924–931.
6. Ishchenko AI, Zhumanova EN, Ishchenko AA. Modern approaches in diagnostics and organ-preserving treatment of adenomyosis. Obstet Gynecol Reprod. 2013;7:30–34.
7. Culley L, Law C, Hudson N, et al. The social and psychological impact of endometriosis on women’s lives: A critical narrative review. Hum Reprod Update. 2013;19:625–639.
8. Harada T, Khine YM, Kaponis A, Nikellis T, Decavallas G, Taniguchi F. The impact of adenomyosis on women’s fertility. Obstet Gynecol Surv. 2016;71:557–568.
9. National Institute for Health and Care Excellence. Endometriosis: diagnosis and management. NICE guidelines September 2017. 2017. https://www.nice.org.uk/guidance/ng73/resources/endometriosisdagnosis-and-management-pdf-1837632548293. Accessed September 7, 2017.
10. Batzer FR. GnRH analogs: Options for endometriosis-associated pain treatment. J Minim Invasive Gynecol. 2006;13:539–545.
11. Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian J Endocrinol Metab. 2011;15:261–267.
12. Prentice A, Deary AJ. Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;(2):CD000346.
13. Ipsen. Decapeptyl SR 3.75 mg summary of product characteristics. 2016. https://www.medicines.org.uk/emc/medicine/868-. Accessed August 14, 2017.
14. Fawzy M, Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: A prospective clinical trial. Arch Gynecol Obstet. 2015;292:1267–1271.
15. Kang JL, Wang XX, Nie ML, Huang XH. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest. 2010;69:73–77.
16. Wong AV, Tang L. An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis. Fertil Steril. 2004;81:1522–1527.
17. Leone Roberti Maggiore U, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother. 2014;15:1153–1179.
18. Demidov VN, Adamyan LV, Chachaturyan AK. Ultrasound diagnosis of endometriosis. II. Internal endometriosis [Ультразвуковая диагностика эндометриоза. II. Внутренний эндометриоз] Article in Russian. Ultrasonic Diagnostics. 1996;1:32–42.
19. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice. 1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Accessed October 4, 2012.
20. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed October 4, 2012.
21. Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3–13.
22. Nieboer TE, Johnson N, Lethaby A, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2009;(3):CD003677.
23. Khan KN, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25:642–653.
24. De Falco M, Pollio F, Pontillo M, et al. GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: Literature review. Article in Spanish. Minerva Ginecol. 2006;58:553–560.
25. Di Lieto A, De Falco M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone
analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12:123–128.

26. Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22:307–331.

27. Parker WH. Uterine myomas: Management. Fertil Steril. 2007;88:255–271.

28. Campo S, Campo V, Benagiano G. Infertility and adenomyosis. Obstet Gynecol Int. 2012;2012:786132.

29. Matalliotakis IM, Katsikis IK, Panidis DK. Adenomyosis: What is the impact on fertility? Curr Opin Obstet Gynecol. 2005;17:261–264.

30. Sharma S, Agarwal N, Chetani M, et al. Does presence of adenomyosis effect reproductive outcome – a retrospective analysis of 607 patients having endometriosis, endometriosis with adenomyosis and only adenomyosis who underwent IVF/ICSI. Fertil Steril. 2015;104:e160.

31. Mori H, Taketani Y, Uemura T, Miyake A, Tango T. Rates of endometriosis recurrence and pregnancy 1 year after treatment with intranasal buserelin acetate (Suprecur) (a prospective study). J Obstet Gynaecol Res. 1999;25:153–164.

32. Appiah D, Schreiner PJ, Bower JK, Sternfeld B, Lewis CE, Wellons MF. Is surgical menopause associated with future levels of cardiovascular risk factor independent of antecedent levels? The CARDIA study. Am J Epidemiol. 2015;182:991–999.

33. Duru C, Jha S, Lashen H. Urodynamic outcomes after hysterectomy for benign conditions: A systematic review and meta-analysis. Obstet Gynecol Surv. 2012;67:45–54.

34. Forsgren C, Lundholm C, Johansson AL, Cnattingius S, Zetterstrom J, Altman D. Vaginal hysterectomy and risk of pelvic organ prolapse and stress urinary incontinence surgery. Int Urogynecol J. 2012;23:43–48.

35. McPherson K, Metcalfe MA, Herbert A, et al. Severe complications of hysterectomy: The VALUE study. BJOG. 2004;111:688–694.

36. Hirata T, Izumi G, Takamura M, et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: A pilot study. Gynecol Endocrinol. 2014;30:726–729.

37. Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2011;157:212–216.

38. Imai A, Takagi H, Matsunami K, Satoshi I. Sequential management with gonadotropin-releasing hormone agonist and dienogest of endometriosis-associated uterine myoma and adenomyosis. In: Chaudhury K, ed. Adenomyosis, Endometriosis - Basic Concepts and Current Research Trends. IntechOpen; 2012:483–490. https://doi.org/10.5772/29647

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. CONSORT patient flow diagram.

Figure S2. Change in endometriosis stage from baseline during triptorelin treatment (effectiveness set). At visit 2, 89 patients had an improvement from stage I endometriosis, but an option for “not applicable/no signs of endometriosis” was not available on the case report form; therefore, these data have not been included.

Table S1. Classification of stages of adenomyosis according to Demidov et al.18a

Table S2. Patient disposition and treatment exposure.

Table S3. Heavy menstrual bleeding (HMB) dynamics during triptorelin treatment in patients with adenomyosis and myoma (effectiveness set).

Table S4. Pelvic pain intensity at baseline (effectiveness set).

Table S5. Change in pelvic examination parameters during triptorelin treatment (enrolled set).

Table S6. Adverse events reported by investigators during the study (enrolled set).